Clinical trials: Metastatic Malignant Neoplasm to Brain
Breast Cancer Brain Metastases
Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in breast cancer Patients with brain metastases.
- Trial name
- NCT05872347
- Testing
- SPH4336 Tablets
- Where
- 25 sites in China
- Volunteers
- 52 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Breast Cancer, Lung Neoplasms
GRN1005 for Brain Metastases From Breast or Lung Cancer
Background: Brain metastases are cancer cells that have spread to the brain from primary cancers in other organs. These tumors can be removed surgically.
- Conditions
- Breast Cancer, Lung Neoplasms, Breast Neoplasms, Lung Cancer
- Trial name
- NCT01679743
- Testing
- Trastuzumab, GRN 1005
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
Expanded Access to ANG1005 for Individual Patients
This is an expanded access study with ANG1005 treatment for two individual patients from Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III Anaplastic Oligodendroglioma and one individual patient…
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Breast Cancer With Recurrent Brain Metastases, Leptomeningeal Carcinomatosis
- Trial name
- NCT02755987
- Testing
- ANG1005
- Where
- 2 sites in United States
- Sponsor
- Angiochem Inc
Brain Metastases, Documented Her2 Overexpression
64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets
This is a single arm pilot study of 64Cu-MM-302 and unlabeled MM-302 in combination with trastuzumab in 10 patients with advanced HER2+ cancer with new or progressive brain metastases.
- Conditions
- Brain Metastases, Documented Her2 Overexpression, Advanced Solid Tumor, Neurologically Stable
- Trial name
- NCT02735798
- Testing
- MM-302, Trastuzumab
- Sponsor
- Pamela Munster
Radionecrosis of Brain, Brain Metastases
Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases
Brain metastases (BM) afflict a significant portion of cancer patients, ranging from 10% to 50%, leading to debilitating symptoms and diminished quality of life, thereby impacting overall survival.
- Trial name
- BRADI (NCT06471465)
- Testing
- Bevacizumab, Prednisolone
- Where
- 10 sites in France
- Volunteers
- 84 people
- Sponsor
- Institut Cancerologie de l'Ouest
Metastatic Non Small Cell Lung Cancer
A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases
20-40% of patients with NSCLC will develop brain metastases at some point during their course of disease. Osimertinib has demonstrated intracranial activity in EFGR mutated NSCLC with leptomeningeal disease in the phase 1 BLOOM…
- Trial name
- OUTRUN (NCT03497767)
- Testing
- Osimertinib, Stereotactic Radiosurgery (SRS)
- Where
- 13 sites in Australia, Singapore
- Volunteers
- 40 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Carcinoma, Non-Small -Cell Lung
Analysis of Brain Metastasis in Patients With Lung Cancer
This study will examine patients with non-small cell lung cancer metastasis, that is, the distant spreading of tumors to the brain, and compare them with patients without brain metastasis.
- Trial name
- NCT00071344
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Non Small Cell Lung Cancer, Brain Metastases
Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases
The purpose of this study was to investigate the efficacy and safety of Cadonilimab combined with bevacizumab and chemotherapy for advanced non-squamous NSCLC with untreated brain metastases.
- Trial name
- CBC (NCT05812534)
- Testing
- Cadonilimab
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Brain Metastases
Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases
Vorinostat in combination with radiation therapy can be administered safely and will be tolerated in patients with brain metastases, while providing an assessment of the anti-tumor activity of this combination.
- Trial name
- NCT00838929
- Testing
- Vorinostat, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Brain Metastases, Adult
SIMT Stereotactic Radiosurgery Outcomes Study
The purpose of this study is to determine the effectiveness and efficiency of Single Isocenter Multi-target Stereotactic Radiosurgery (SIMT SRS) in patients with four or more brain metastases
- Trial name
- SIMT (NCT02886572)
- Testing
- Stereotactic radiosurgery
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Duke University
Cancer Metastatic to Brain, Brain Metastases, Adult
Managing Distress in Malignant Brain Cancer
To identify potential adaptations of the managing cancer and living meaningfully (CALM) intervention that will be required for service members, Veterans, their beneficiaries, and civilian cancer metastasis to the brain (bMET)…
- Trial name
- NCT05087095
- Testing
- CALM Intervention
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Virginia Commonwealth University
Brain Tumor, Primary, Brain Tumor - Metastatic
Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors
The goal of this observational study is to characterize the circulating leukocyte profile and the immune T cells distribution within the tumor in patients with malignant brain tumors and to correlate these findings with the…
- Trial name
- NCT05831631
- Testing
- Circulating leukocytes immunophenotype, Tumor sampling
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Pietro Mortini, MD, Prof.
Brain Tumor, Brain Necrosis
Development of MRF for Characterization of Brain Tumors After Radiotherapy
The purpose of this study is to discover the potential convenience and ease of using a Magnetic Resonance Imaging (MRI) technique, named Magnetic Resonance Fingerprinting (or MRF), to achieve high-quality images within a short…
- Conditions
- Brain Tumor, Brain Necrosis, Brain Metastases, Glioma
- Trial name
- NCT06101069
- Testing
- MRF in conjunction with IVIM MRI without contrast
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Case Comprehensive Cancer Center
Brain Metastasis
IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine (CQ) in Brain Metastasis Radiotherapy
This research is being done to determine if a short course of Chloroquine (five weeks) before, during and after whole brain radiation therapy (WBRT) will improve the overall survival of subjects being treated for brain metastases.
- Trial name
- NCT01727531
- Testing
- Chloroquine diphosphate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Main Line Health
Melanoma, Non-small Cell Lung Carcinoma (NSCLC)
LITT and Pembrolizumab in Recurrent Brain Metastasis
This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with…
- Conditions
- Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC), Small-cell Lung Cancer
- Trial name
- TORCH (NCT04187872)
- Testing
- LITT + Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Florida
Recurrent Glioma, High-grade Meningioma
Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors
This is an open label phase I clinical trial with two arms, representing single and fractionated radiation therapy (Figure 4.1). Within each arm the radiation dose is pre-determined and not escalated.
- Conditions
- Recurrent Glioma, High-grade Meningioma, Brain Metastasis
- Trial name
- NCT01324635
- Testing
- Panobinostat, Stereotactic body radiation therapy, Quality-of-life assessment
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Brain Metastasis
Prospective Randomized Trial Between WBRT Plus SRS Versus SRS Alone for 1-4 Brain Metastases
The purpose of this study is to determine if WBRT combined with SRS resulted in improvements in survival, brain tumor control, functional preservation rate, and frequency of neurologic death.
- Trial name
- NCT00406835
- Testing
- Whole-Brain Radiation Therapy, Stereotactic Radiosurgery
- Where
- Japan
- Volunteers
- 180 people
- Sponsor
- Hokkaido University Hospital
Glioblastoma Multiforme, Brain Metastases
PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404
The purpose of this study is to evaluate diagnostic imaging techniques using 124I-NM404 PET/CT in human brain tumors. This goal will be accomplished by quantifying tumor uptake and determining the optimal PET/CT protocol…
- Trial name
- NCT01540513
- Testing
- NM404
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Wisconsin, Madison
Brain Metastases
Use of AlignRT System During Stereotactic Radiosurgery
This prospective study evaluated whether the AlignRT surface-guided radiotherapy system improves patient positioning accuracy during stereotactic radiosurgery (SRS) for brain metastases compared with standard manual positioning.
- Trial name
- NCT07716124
- Testing
- Manual Patient Positioning, AlignRT-Guided Patient Positioning
- Where
- Slovenia
- Volunteers
- 20 people
- Sponsor
- Institute of Oncology Ljubljana
Breast Cancer
Efficacy and Safety of Inetetamab Plus Pyrotiniband and Capecitabine in HER2-positive Metastatic Breast Cancer Patients With or Without Brain Metastasis
This study intends to include HER2-positive metastatic breast cancer patients (with or without brain metastasis) who have become resistant to previous treatment with trastuzumab.
- Trial name
- NCT06015100
- Testing
- Inetetamab plus pyrotiniband and capecitabine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Yan Xue
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.